DAT imaging in drug-induced and psychogenic parkinsonism
- 1 October 2003
- journal article
- review article
- Published by Wiley in Movement Disorders
- Vol. 18 (S7) , S28-S33
Abstract
Parkinson's syndrome (PS) is frequently encountered in disorders associated with prominent degeneration of the nigrostriatal pathway as in Parkinson's disease, multisystem atrophy, and progressive supranuclear palsy (presynaptic PS). Drug‐induced parkinsonism, a common, underdiagnosed health problem and psychogenic parkinsonism are causes of Parkinson's syndrome which, evidence suggests, occurs without degeneration of nigrostriatal structures. We review clinical features and results of DAT imaging in drug‐induced parkinsonism and psychogenic parkinsonism. These two conditions normally give normal striatal DAT imaging results; an abnormal result in either case could exclude both conditions, corroborating a diagnosis of organic parkinsonism in uncertain cases. © 2003 Movement Disorder SocietyKeywords
This publication has 49 references indexed in Scilit:
- Drug-Induced Movement DisordersDrug Safety, 1997
- A long‐term follow‐up study of cinnarizine‐ and flunarizine‐induced parkinsonismMovement Disorders, 1997
- Adverse Effects of Antipsychotic AgentsDrugs, 1996
- Comparison of [3H]WIN 35,428 Binding, a Marker for Dopamine Transporter, in Embryonic Mesencephalic Neuronal Cultures with Striatal Membranes of Adult RatsJournal of Neurochemistry, 1993
- Cinnarizine-Induced Parkinsonism in PrimatesClinical Neuropharmacology, 1992
- Psychogenic dyskinesias in patients with organic movement disordersMovement Disorders, 1990
- Coexistent Tardive Dyskinesia and ParkinsonismClinical Neuropharmacology, 1987
- Extrapyramidal effects of neuroleptics.Journal of Neurology, Neurosurgery & Psychiatry, 1976
- Prolonged Drug-Induced ParkinsonismStereotactic and Functional Neurosurgery, 1973
- LEVODOPA IN DRUG-INDUCED EXTRAPYRAMIDAL DISORDERSThe Lancet, 1970